Skip to main content
OSCOTECInc. logo

OSCOTECInc. — Investor Relations & Filings

Ticker · 039200 ISIN · KR7039200001 KO Manufacturing
Open in API
Filings indexed 271 across all filing types
Latest filing 2025-04-18 Regulatory Filings
Country KR South Korea
Listing KO 039200

About OSCOTECInc.

https://oscotec.com/

Oscotec Inc. is a clinical-stage drug discovery and development company focused on translating scientific research into innovative medicines for clinically unmet needs. The company's development pipeline targets various diseases, with a primary focus on immunology, oncology, and neurodegenerative disorders. Key therapeutic areas include rheumatoid arthritis, immune thrombocytopenia, non-small cell lung cancer, acute myeloid leukemia, and Alzheimer's disease. Oscotec specializes in developing novel kinase inhibitors, such as Spleen Tyrosine Kinase (SYK) inhibitors, to address these conditions.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(임상시험계획승인신청) (면역성 혈소판감소증(ITP)의 1차 치료법 가능성에 대한 탐색적 2상 연구자 주도 임상시험 IND 신청)
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from a Korean company (Oscotec) regarding an application for clinical trial approval (IND) for a Phase 2 study. It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) required by the Korea Exchange (KRX). Since it details a specific regulatory event (clinical trial application) and does not fit into the other specific categories like financial reports or shareholder meetings, it is classified as a Regulatory Filing (RNS).
2025-04-18 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership, specifically regarding the major shareholder (Kim Jung-kun) and special related parties (directors/executives) of Oscotec. Since this document reports significant changes in shareholding and ownership structure, it falls under the 'Major Shareholding Notification' category.
2025-04-18 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by an executive (Kim Jung Kun) of Oscotec. This type of filing is a standard regulatory requirement for reporting insider shareholdings and changes in ownership, which falls under the 'Director's Dealing' category.
2025-04-18 Korean
대표이사변경
Board/Management Information Classification · 1% confidence The document is a formal announcement regarding a change in the company's leadership structure, specifically transitioning from a single CEO to co-CEOs. It explicitly lists the names of the outgoing/incoming representatives, the reason for the change, and the effective date. This falls directly under the category of board or management changes.
2025-04-14 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an official report of the results of an Annual General Meeting (AGM) for the company 'OscoTec'. It details the outcomes of various agenda items, including financial statement approval, board member appointments, and changes to the articles of incorporation. This falls directly under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it provides the official record of shareholder votes and meeting outcomes.
2025-03-27 Korean
대표이사변경
Board/Management Information Classification · 1% confidence The document is a formal announcement regarding a change in the company's representative director (CEO) from a joint representative structure to a sole representative structure. This falls directly under the category of board and management changes.
2025-03-27 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.